Dr. Reddy's Laboratories Ltd. Share Price

Overview

Dr. Reddy's Laboratories Ltd. share price is currently ₹1,378.50, up by ₹3.04 (0.22%) from its previous closing price of ₹1,375.46. The share price has gained 12.47% over the past month and gained 12.23% over the past year. The stock's 52-week low and high are ₹1,088.94 and ₹1,397.94, respectively. Dr. Reddy's Laboratories Ltd. has a market capitalisation of ₹ 1,16,770.96 Cr. The share price was last updated on 20 Nov 2026, 03:57 PM IST.

Dr. Reddy's Laboratories Ltd.
Dr. Reddy's Laboratories Ltd.
DRREDDY
 ₹0.00
 ₹3.04
0.22%
Healthcare
 ₹0.00(%)1D

Updated: 20 Nov 2026, 03:57:14 pm IST

Market Data

Open Price

 ₹1,389.35

Prev. Close

 ₹1,375.46
 ₹1,373.07

Day Low

 ₹1,389.35

Day High

 ₹1,088.94

52 Week Low

 ₹1,397.94

52 Week High

HealthcarePharmaceuticals & Drugs
CategoryLarge Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

41.11

Sector PE

45.96

PB Ratio

3.05

Sector PB

6.03

EPS

33.53

Dividend Yield

0.64

Today's Volume

864.709 K

5 Day Avg. Volume

1.166 M

PEG Ratio

-1.59

Market Cap.

₹ 1,16,770.96 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

ActionsEx-DateRecord-Date
DividendsFinal Dividend of 800% at ₹8/Share
10-Jul-202610-Jul-2026
DividendsFinal Dividend of 800% at ₹8/Share
10-Jul-202510-Jul-2025
Stock Split1:5
28-Oct-202428-Oct-2024

Mutual Fund Ownership

Mutual Fund Holder
Sep 26
Shares held
Oct 26
Shares held
Parag Parikh Flexi Cap Fund - Regular Plan - Growth1.45 Cr
1.46 Cr
(0.9%)
SBI Nifty 50 ETF1.18 Cr
1.18 Cr
(0.16%)
ICICI Prudential Value Fund - Growth95.69 Lac
95.69 Lac
no change
ICICI Prudential India Opportunities Fund - Growth78.45 Lac
80.57 Lac
(2.7%)
ICICI Prudential Large Cap Fund - Growth63.19 Lac
63.19 Lac
no change

About Dr. Reddy's Laboratories Ltd. 👋

Dr. Reddy's Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.

Analyst Opinions

Insights from SEBI-registered analysts · updated live

Explore all →
Palak Jain

Palak Jain

15 Nov • 11:17 PM · SEBI-Registered Analyst

Dr Reddy’s Expands Its Global Pharmaceutical Portfolio

A pharmaceutical company's growth is not just about launching more medicines. Getting regulatory approvals and expanding into new markets can be equally important. Dr. Reddy’s Laboratories recently announced a development worth tracking. The company continues to strengthen its presence across international pharmaceutical markets, with a focus on expanding its portfolio of generic medicines and complex formulations. Why does this matter? DRREDDY The global generic medicines market offers opportunities for Indian pharmaceutical companies because healthcare systems are constantly looking for cost-effective treatment alternatives. But entering these markets is not easy. Companies need to navigate: - Regulatory approvals from authorities such as the US FDA. - Competition from established generic drug manufacturers. - Pricing pressure in international markets. - Manufacturing quality and compliance requirements. For Dr. Reddy’s, the important factors to watch are new product launches, US business performance, regulatory developments and growth in emerging markets. The Indian pharma industry has global ambitions, but consistent execution and product quality will determine which companies can sustain that growth. *Educational purpose only. Not investment advice.* Source: [Nifty 100 corporate announcements](***** and company disclosures.

See More
Ankit Gupta

Ankit Gupta

15 Nov • 12:06 PM · SEBI-Registered Analyst

Dr. Reddy's Gets VAI Classification for Hyderabad Unit

DRREDDY 'S LABORATORIES: Dr. Reddy's Laboratories has received a Voluntary Action Indicated (VAI) classification from the United States Food and Drug Administration (USFDA) following a Good Manufacturing Practices (GMP) inspection at its formulations manufacturing facility, FTO-3, located in Bachupally, Hyderabad. The company informed the stock exchanges that the USFDA has classified the inspection outcome as VAI and officially closed the inspection under 21 CFR 20.64(d)(3). The inspection was conducted between August 6 and August 14, 2026, and the company had earlier disclosed that it received a Form 483 containing four observations. The company subsequently provided its responses within the stipulated timeline. The latest update confirms the regulatory classification and formal closure of the inspection process. VAI stands for Voluntary Action Indicated and represents the USFDA's classification of the inspection outcome. This is a regulatory development relating specifically to the FTO-3 formulations facility in Hyderabad. The outcome is an important corporate update for Dr. Reddy's Laboratories, particularly in the context of regulatory compliance and manufacturing operations. Market participants may track further regulatory disclosures and company updates for developments concerning its manufacturing facilities. Overall, the USFDA has classified the FTO-3 Hyderabad facility inspection as VAI and confirmed its official closure, following the GMP inspection conducted in August 2026. This information is shared strictly as a corporate and market update for informational purposes and should not be considered investment advice, research analysis, or a recommendation to buy or sell any security.

See More
Akshay Patel

Akshay Patel

5 Nov • 11:39 PM · SEBI-Registered Analyst

DRREDDY get generic Semaglutide injection approval in Brazil

Dr. Reddy’s Laboratories Limited (NSE: DRREDDY) DRREDDY has received regulatory approval in Brazil for its generic Semaglutide injection, for adults with uncontrolled type 2 diabetes. The estimated addressable market for generic semaglutide in Brazil is $800 million. What happened: Dr. Reddy’s will launch with Aché, a Brazilian pharmaceutical manufacturer, under a co-commercialization partnership. Brazil follows earlier product filings in Canada and India. The company targets a combined supply of 6 million to 7 million semaglutide injector pens across key markets in H2 FY27. Why it matters: Brazil gives Dr. Reddy’s a large GLP-1 market where the company can sell. It also adds a growth line as older generics lose revenue after the loss of exclusivity on legacy oncology brands. My view: Treat $800 million as the size of the pool, not Dr. Reddy’s revenue. Approval is a permit. Sales depend on supply, and supply depends on the pen scale-up. The Q1 FY27 batch provision of ₹239.7 crore on semaglutide API shows what the ramp-up has cost so far. Aché brings local distribution and retail access, which cuts entry risk. Profit sharing terms are not disclosed, so margin impact is uncertain. Pricing will also come under pressure as more generic filers enter. What I am watching: the Brazil launch date with Aché, the Q3 relaunch of the Obeda brand, and whether pen supply tracks the H2 FY27 target. Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations.

See More
Ujvin Nevatia

Ujvin Nevatia

5 Nov • 12:41 PM · SEBI-Registered Analyst

Dr. Reddy's secures Brazil approval for semaglutide

Research Analyst: UJVIN NEVATIA (PROPRIETOR: NEVAT INVESTMENTS) | SEBI Registration No.: INH100009628 Dr. Reddy's Laboratories Limited ( DRREDDY ) has received marketing authorisation from Brazil's health regulator, ANVISA, for its generic semaglutide injection. The approval allows the company to expand its presence in the Latin American market. What happened? The product is indicated for adults with insufficiently controlled Type 2 diabetes and will be available as a pre-filled, multi-dose injectable pen in two presentations: 2 mg/1.5 mL and 4 mg/3 mL. It is designed for once-weekly administration. Dr. Reddy's plans to launch the product in Brazil in partnership with Aché. Brazil represents a significant potential market, with approximately 16.6 million adults aged 20–79 living with diabetes. The company's statement estimates the country's semaglutide market for diabetes at around $244.6 million. Why does it matter? The approval expands Dr. Reddy's semaglutide presence beyond India and strengthens its entry into a key Latin American market. It also marks regulatory progress after ANVISA rejected its earlier application in April 2026 over technical requirements. My view This approval is an important step in the company's global generics strategy. Semaglutide offers a potential growth opportunity, but commercial success will depend on launch execution, pricing, competition and the ability to maintain product quality and supply. What I am watching next I would track the Brazilian launch timeline, market penetration, pricing strategy, partnership execution and further regulatory approvals across international markets. No Recommendations Source: Business Standard Disclosure: I, my entity, associates or relatives do not have any holding, position or other material interest in Dr. Reddy's Laboratories Limited.

See More
Harika Enjamuri

Harika Enjamuri

3 Nov • 12:00 PM · SEBI-Registered Analyst

Dr Reddy’s gets USFDA nod for HIV prevention drug

Dr. Reddy’s Laboratories Limited has received tentative USFDA approval for its twice-yearly injectable lenacapavir for HIV prevention, covering 120 countries outside the US. The generic injection will be priced at $40 per person annually under its licensing agreement with Gilead Sciences. The approval covers HIV-1 pre-exposure prophylaxis (PrEP) for adults and adolescents weighing at least 35 kg. Dr. Reddy’s received the voluntary licence from Gilead in October 2024 and later partnered with Unitaid, Wits RHI and CHAI to accelerate development and regulatory approval. Initial supplies are expected before the end of 2026, followed by wider availability in 2027. My view: This approval strengthens Dr. Reddy’s position in complex generic injectables and opens access to a large international public health market. However, the $40 annual price makes scale, procurement volumes and manufacturing efficiency important for commercial returns. The opportunity is significant, but revenue contribution will depend on how quickly countries adopt the product. Investors should watch for initial supply orders, production ramp-up and commercial progress through 2027. Dr. Reddy’s shares traded at ₹1,352.90 on the NSE, up 0.81%. Stance: Positive from a business development perspective. Execution and actual order volumes will determine the financial impact. DRREDDY Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.

See More
Vimal K

Vimal K

2 Nov • 10:01 PM · SEBI-Registered Analyst

Nifty Outlook for 03-Nov-2026 looks Bullish

The Nifty 50 closed on Monday, November 2, 2026, with a strong surge of 1.68% at 23,440.80, hitting its intraday high of the session. The index cleared its 20-day and 50-day moving averages, fueled by heavyweights like Reliance Industries, Tata Steel, and broad-based sectoral participation. The Daily MACD Histogram is above zero and the Hourly MACD Histogram is also above zero indicating a bullish trend. The Daily RSI 14 at 61.03 above the midline 50 levels indicate a bullish trend and the Hourly RSI 14 is at the overbought territory above the 70 levels at 74.33 also indicate a bullish trend. But we may see a consolidation or a correction. Thus, the overall trend of Nifty looks bullish, and the buyers are in control over the markets. Buy on dips would be the best strategy to deploy for today’s market considering the overall trend of Nifty. We may expect a change in trend only if the price sustains below the support level. Can Initiate selling only if prices continue to sustain below the support level. I have provided Nifty Spot resistance and support levels which would help you learn in taking informed trading decisions using these levels and understand how support and resistance levels work in financial markets. Nifty Spot Resistance 1 - 23505 Resistance 2 - 23525 Support 1 - 23245 Support 2 - 23185 Happy Learning, Happy Trading and have a wonderful day Top Gainers : RELIANCE, JSWSTEEL, TATASTEEL. Top Losers : INFY, ICICIBANK, DRREDDY. RELIANCE

See More

News & Events

Frequently Asked Questions

What is the share price of Dr. Reddy's Laboratories Ltd.?

What is the market cap of Dr. Reddy's Laboratories Ltd.?

Should I buy Dr. Reddy's Laboratories Ltd. stock now?

What is the 52 week high and low of Dr. Reddy's Laboratories Ltd.?

Is the Dr. Reddy's Laboratories Ltd. stock good to buy?

Is Dr. Reddy's Laboratories Ltd. a good buy for the long term?

Is Dr. Reddy's Laboratories Ltd. overvalued or undervalued?

What is the PE and PB ratio of Dr. Reddy's Laboratories Ltd.?

Start Now